Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy

POXEL SA announced that the FDA has granted Fast Track Designation to PXL770 for the treatment of patients with adrenomyeloneuropathy, the most common form of X-linked adrenoleukodystrophy.